Hoth Therapeutics Inc. experienced a dramatic surge in its stock price on Wednesday, with shares climbing approximately 71% to $1.21 in heavy Nasdaq trading, after touching an intraday high of $1.54. The dramatic move came after the clinical-stage biotechnology company announced it had completed its legal name change to Rocket One Inc. and would begin trading under the new ticker symbol RKTO on the Nasdaq Capital Market starting May 28.
The pivot represents a fundamental transformation of the company's market narrative. Rocket One will now focus on space, defense, and nanomagnetic AI chip technology, leaving its legacy drug development programs in a wholly owned subsidiary. The company's common stock will cease trading under the HOTH ticker at the close of business on May 27.
Chief Executive Robb Knie framed the shift as a strategic move into what he called the 'orbital economy.' In a statement, Knie noted that 'space is moving from a launch story to a compute story,' and the new RKTO ticker signals the company's commitment to this emerging sector. The nanomagnetic AI chip technology, which utilizes nanoscale magnetism rather than traditional silicon-based electron flow, is designed for low-power, radiation-tolerant computing applications in satellites and defense systems.
While the market's immediate reaction was overwhelmingly positive, the company's financial fundamentals remain challenging. In its latest quarterly filing, Hoth reported no revenue, a net loss of approximately $2.7 million for the first quarter, cash and equivalents of about $4.0 million as of March 31, and an accumulated deficit of roughly $75.6 million. The filing noted that these conditions 'raise substantial doubt about the company's ability to continue as a going concern,' underscoring the urgent need for additional capital.
The stock's rally, if sustained above the $1 threshold, could help address a separate regulatory issue. Hoth had previously received a notice from Nasdaq for non-compliance with the exchange's minimum bid-price rule, after its shares traded below $1 for 30 consecutive business days. The company has until October 27 to regain compliance by closing at or above $1 for at least 10 consecutive business days.
The company's legacy biotechnology assets, including programs HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic therapy, will continue under a subsidiary. Notably, just one day before the rebranding announcement, Hoth revealed that the U.S. Patent and Trademark Office had issued a notice of allowance for its HT-KIT therapeutic, a mast-cell disease program. Knie described this patent action as 'meaningful validation' of the platform, and the company expects to finalize an investigational new drug submission in 2026.
Rocket One's new focus places it in a competitive landscape that includes companies like Rocket Lab, which positions itself as an end-to-end space company covering launches, spacecraft design, satellite components, and flight software, and Redwire, an integrated space and defense technology firm that uses AI-enabled autonomous operations across multiple domains and orbits.
However, the company's risk disclosures highlight significant challenges. The licensed chip technology is still early-stage, has no commercial product, and has not been validated in space environments. Rocket One also cited the need for substantial capital, long semiconductor development timelines, the presence of larger competitors, license milestones, intellectual-property risks, and export-control issues tied to defense and space work. The rally, while impressive, does not by itself validate the new technology plan, generate revenue, or eliminate the need for future financing.
